Log in | Register

Nycomed Names New Chief Executive Officer

For the latest pharmaceutical news and updates - Sign up now!
Loading...

Nycomed US Inc. today announced the appointment of Steve Andrzejewski as the new Chief  Executive Officer. He assumes immediate responsibility for Nycomed US Inc., including manufacturing in Melville and Hicksville, New York, distribution and commercial operations for the three marketing and  sales divisions Fougera, PharmaDerm and Savage Laboratories.

Steve Andrzejewski has been working in the pharmaceutical and healthcare industry for more than 20 years. He joins from King Pharmaceuticals where he served as Corporate Head, Commercial Operations first and then as Chief Commercial Officer.

He holds a Bachelor's degree in Psychology from Hamilton College in  New York, and an MBA in Finance/International Business from New York  University. Steve Andrzejewski began his career as a sales  representative at Schering-Plough Corporation, and rose steadily through the ranks over the next 16 years. From 1998 on he held a number of Vice President positions at Schering-Plough, including  Marketing and New Products. Before joining King Pharmaceuticals, he was the Senior Vice President of the Commercial Business at Endo Pharmaceuticals.

"I am delighted to welcome Steve Andrzejewski as our new Chief  Executive Officer for Nycomed's US business," says Hakan Bjorklund, Chief Executive Officer of Nycomed. "His experience with both generics and proprietary products will be great assets to guide Nycomed US  through the challenging and changing business environment."     

 

Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Tale of Two Deviations

The Tale of Two Deviations

Apr 23 | The QA Pharm

It stands to reason that pharmaceutical companies in compliance trouble also have problems with their Deviation Management and Corrective and Preventive Action (CAPA) System(s).

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Apr 16 | Girish Malhotra, PE, President, EPCOT International

The answer is an unequivocal yes but we need some outsiders who can conspire with the insiders who will be the flag bearers within the companies. Outsiders can be the counsels/co-conspirators to the insiders for the coup d'etat.

Multimedia

Lung Cancer Drug Treats Rare Lymphoma Tumors

Lung Cancer Drug Treats Rare Lymphoma Tumors

May 17 | Video

A new study found Xalkori effective in treating anaplastic lymphoma among children, an encouraging development for gene-targeted therapy.

Merck - 2012 Facility of the Year Award - Facility Integration

Merck - 2012 Facility of the Year Award - Facility Integration

May 14 | Video

Brian Morrissey, Senior Project Engineer, Merck Manufacturing Division, talks to Pharmaceutical Processing's Editor In Chief Mike Auerbach during INTERPHEX 2012 about the company's Vaccine Bulk Manufacturing Facility Program of Projects. The facility has won the Facility Integration award in the 2012 Facility of the Year Award competition sponsored by ISPE, INTERPHEX and Pharmaceutical Processing magazine.

Medicine from a Vending Machine?

Medicine from a Vending Machine?

May 3 | Video

A Chinese company is pushing for acceptance of traditional Chinese medicine with a machine that can dispense herbs.

Taking Precautions to Prevent Contagion

Taking Precautions to Prevent Contagion

Apr 29 | Video

With the recent outbreak of viruses such as SARS, bird flu and swine flu, officials and travelers are being extra careful about preventing the illnesses from being transmitted.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter